# US 11,896,724 B2 · Bioactive polymeric dressing for accelerated wound closure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,724 B2
- Document ID: US11896724B2
- Status: Granted
- Kind: B2
- Application number: 17/065,283
- Filed: 2020-10-07
- Published: 2021-04-08
- Granted: 2024-02-13
- Earliest claimed: 2019-10-07
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Applicants: Arizona Board of Regents on behalf of Arizona State University
- Inventors: Kaushal Rege; Deepanjan Ghosh
- Web page: https://patentgrep.com/patent/US11896724B2

## CPC

- A61L 15/44: Medicaments
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 33/242: Gold; Compounds thereof
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61L 15/18: containing inorganic materials
- A61L 15/20: containing organic materials
- A61L 15/32: Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)}
- A61L 26/0004: {containing inorganic materials}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61L 26/0095: {Composite materials, i.e. containing one material dispersed in a matrix of the same or different material}
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61N 5/0616: {Skin treatment other than tanning}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61L 2300/102: Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L 2300/414: Growth factors
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61N 5/067: using laser light
- A61N 2005/0659: {infrared}
- A61N 2005/0662: {Visible light}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.

## Claims

### Claim 1

A wound dressing comprising:
a structural material formed into a dressing, wherein the structural material ranges from about 2-25 wt %;
at least one immunomodulatory agent associated with the dressing; and
a growth factor associated with the dressing;
wherein the wound dressing comprises gold particles in the structural material; and;
wherein the growth factor is associated with the gold particles.

### Claim 2 (depends on 1)

The wound dressing of claim 1, wherein the structural material is biodegradable and/or bioabsorbable.

### Claim 3 (depends on 1)

The wound dressing of claim 1, wherein the structural material is a natural substance or a natural substance that has been chemically modified.

### Claim 4 (depends on 1)

The wound dressing of claim 1, wherein the structural material is a synthetic substance.

### Claim 5 (depends on 1)

The wound dressing of claim 1, wherein the immunomodulatory agent is selected from the group consisting of histamine, histamine receptor agonists, MCP1, antibodies, 2-pyridylethylamine, histamine-trifluoromethyl-toluidine dimaleate (HTMT), diphenhydramine, terfenadine, dimaprit, cimetidine, ranitidine, Nα-methylhistamine, azomethine prodrug of (R)-α-methylhistamine, impentamine, clobenpropit, immepip, imetit, 4-Methylhistamine and combinations thereof.

### Claim 6 (depends on 1)

The wound dressing of claim 1, wherein the growth factor is selected from the group consisting of stromal cell-derived factor (SDF1), basic fibroblast growth factor (bFGF), transforming growth factor (TGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), heat shock protein 90 alpha (HSP90α), F5 subunit of heat shock protein 90 alpha (HSP90α), each optionally fused with elastin-like polypeptide (ELP), and combinations thereof.

### Claim 7 (depends on 1)

The wound dressing of claim 1, further comprising the structural material including a laser stimulated material that is stimulated by near IR laser light of about 650 nm to about 1400 nm.

### Claim 8

A wound dressing kit comprising:
a structural material formed into a wound dressing;
wherein the structural material ranges from about 2-25 wt %;
at least one immunomodulatory agent associated with the dressing; and
a growth factor associated with the dressing;
wherein the wound dressing comprises gold particles in the structural material; and;
wherein the growth factor is associated with the gold particles.

### Claim 9

A method of treating a wound in a tissue comprising:
applying to the wound a first wound dressing comprising:
a structural material formed into a dressing,
wherein the structural material ranges from about 2-25 wt %;
at least one immunomodulatory agent associated with the dressing; and
a growth factor associated with the dressing;
wherein the wound dressing comprises gold particles in the structural material; and;
wherein the growth factor is associated with the gold particles.

### Claim 10 (depends on 9)

The method of claim 9, further comprising:
irradiating the wound through the first wound dressing with at least one laser light having a wavelength of about 700 nm to about 1400 nm, or about 800 nm.

### Claim 11 (depends on 9)

The method of claim 9, wherein the method is devoid of using a suture, staple, clamp, or other structural element with the first wound dressing to treat the wound.

### Claim 12 (depends on 9)

The method of claim 9, further comprising using a suture, staple, clamp, or other structural element with the first wound dressing to fasten the wound dressing to the tissue.

### Claim 13 (depends on 9)

The method of claim 9, further comprising:
removing the first wound dressing from the wound; and
applying a second wound dressing to the wound with or without applying a second administration of immunomodulatory agent and/or growth factor.

### Claim 14 (depends on 9)

The method of claim 9, further comprising applying a second immunomodulatory agent and/or growth factor composition to the wound without removing the first wound dressing from the wound.

### Claim 15 (depends on 9)

The method of claim 9, wherein a subject having the wound in the tissue has diabetes.